Matthias Leisegang

Juniorprofessor

Charité - Universitätsmedizin Berlin

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Matthias Leisegang is a Juniorprofessor at Charité Universitätsmedizin Berlin Campus Berlin Buch, Germany. His research areas focus on T-cell receptor (TCR) therapy, particularly in the context of cancer immunotherapy and the identification of effective TCRs against tumor antigens. Recent articles authored by him explore topics such as the prevention of cancer relapse through mutant p53-specific TCR therapy and the systematic safety pipeline for TCR selection in clinical applications.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (8)

Sten Eirik Waelgaard Jacobsen

Karolinska University Hospital

SWEDEN

View details

Robert Klopfleisch

Friedrich-Loeffler-Institut

GERMANY

View details

Steven Wolf

University of Chicago

UNITED STATES

View details

Leo Hansmann

GERMANY

View details

Takeshi Kurita

Professor

Tokyo Medical and Dental University

JAPAN

View details

Kazutaka Obama

教授 / Professor

Kyoto University

JAPAN

View details

Johanna Olweus

Professor

University of Oslo

NORWAY

View details

Amy Hillen

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Matthias Leisegang

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire

Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases.

CD4 + T cells with convergent TCR recombination reprogram stroma and halt tumor progression in adoptive therapy

Oligonucleotide library screening for identification of virus‐specific T‐cell receptors

One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication

Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system.

Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3

ERAP2 supports TCR recognition of three immunotherapy targeted tumor epitopes.

A systematic safety pipeline for selection of T-cell receptors to enter clinical use

Rapid single-cell identification of Epstein–Barr virus-specific T-cell receptors for cellular therapy

T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes

“Designer cytokines” targeting the tumor vasculature—think global and act local

Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens.

Collaborators (8)

Sten Eirik Waelgaard Jacobsen

Robert Klopfleisch

Steven Wolf

Leo Hansmann

Takeshi Kurita

Kazutaka Obama

Johanna Olweus

Amy Hillen

Make your next move.